All terms
Post-Production Information (Risk)
ISO 14971 requirement to feed real-world post-market data back into the risk management process.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026
Definition
Manufacturers must establish a system to collect and review production and post-production information - complaints, service data, MDRs, literature - and update risk estimates and controls when needed. ISO 14971:2019 clause 10 requires this system, and it ties directly to post-market surveillance under the EU MDR and complaint handling and medical device reporting in the US. Information should also cover the generally acknowledged state of the art, such as new standards, and publicly available data about similar devices. When new information changes a risk estimate, the risk management file and related controls must be updated. What the regulation says
Under EU MDR 2017/745, manufacturers are obligated to plan, establish, document, والر implement a post-market surveillance (PMS) system as detailed in Article 83 and Annex III, which includes gathering post-production information. Similarly, the FDA’s Quality System Regulation, specifically 21 CFR 820.30 (Design Controls), implicitly requires the review of post-production information to ensure design outputs meet user needs and intended uses. ISO 14971:2019, Clause 10 (Post-production information), explicitly mandates the systematic collection and review of information from production and post-production phases to monitor the effectiveness of risk control measures and to identify new hazards or hazardous situations.What this means in practice
PPI is the loop that connects PMS/vigilance to the risk file; weak PPI handling is a common audit finding under MDR.Examples
- A manufacturer analyzes complaint data revealing a recurrent issue with a device’s user interface, prompting a re-evaluation of usability risks and potential design changes.
- Service reports for an imaging device indicate a pattern of component failures after a specific number of operating hours, leading to an update in the device’s maintenance schedule and risk analysis for component longevity.
- Clinical literature review uncovers a new, previously unconsidered adverse event associated with a similar type of MedTech device, prompting the manufacturer to reassess its device’s risk profile and potentially revise its labeling.
Common pitfalls
- •Failing to integrate post-production information review into the overall risk management process can lead to overlooked risks.
- •Treating post-production information collection as a passive activity, rather than an active and systematic process, is a common pitfall.
- •Not adequately documenting the analysis and decisions made based on post-production information can result in deficiencies during audits.
- •Delaying the update of risk management files and clinical evaluations (e.g., CERs, PMCF plans) with new post-production insights is a frequent non-compliance point.
- •Confusing post-production information collection with mere complaint handling, neglecting other crucial data sources, is a narrow interpretation of the requirement.
Frequently asked questions
This includes, but is not limited to, complaints, vigilance reports, service records, maintenance logs, user feedback, scientific literature, clinical experience, and data from Post-Market Clinical Follow-up studies.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Quality & Risk
· Same categoryQuality & Risk
Biocompatibility
Ability of a material to perform with an appropriate host response in a specific application.
Quality & Risk
CAPA Effectiveness Check
Verification step confirming a corrective or preventive action actually fixed the problem.
Quality & Risk
Change Control
Formal QMS process for evaluating, approving, and implementing changes that could affect product quality or compliance.
Quality & Risk
Complaint Handling
Process for receiving, evaluating, and responding to device complaints.
Cited by
Where this term appears across MedTech Terms.
Ecosystems (2)
Latest in MedTech
Sources
3 sourcesSources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.
Tier 1Binding law and standards· 2Tier 2Regulator guidance and consensus· 1
Link health: 3 verified· last checked 2026-06-20
ISO·2AAMI·1
- 1ISO 14971 Cl. 10Tier 1 VerifiedISOiso.org
- 2ISO 13485 Standard PageTier 1 VerifiedISOiso.org
- 3AAMI - Quality Systems ResourcesTier 2 VerifiedAAMIaami.org
Inline markers like [1] jump to the matching reference above.